SCHEMBL6418274

SCHEMBL6418274

CC(C)N1C(=O)c2ccccc2C(C(=O)NCc2ccco2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 4/20 0.47
RECQL P46063 2/20 0.45
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.42
KDM4E B2RXH2 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 3/20 0.41
MAPT P10636 2/20 0.40
PKM P14618 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416926 0.89 MAPK1 (0.62) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6413433 0.89 MAPK1 (0.62) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6420519 0.88 MAPK1 (0.46) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6418317 0.87 MAPK1 (0.45) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6418276 0.86 ALDH1A1 (0.54) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL2936627 0.85 RECQL (0.51) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6413407 0.84 ALDH1A1 (0.66) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6411479 0.82 ALDH1A1 (0.51) MAPK1ALDH1A1RECQLNPC1GAA
SCHEMBL6414124 0.82 MAPK1 (0.61) MAPK1ALDH1A1RECQLGAAKDM4E
SCHEMBL6417309 0.82 ALDH1A1 (0.55) ALDH1A1GAAKDM4ETSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD MAPK1 2656/4885ALDH1A1 1368/4885RECQL 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.